237 related articles for article (PubMed ID: 33118025)
1. Adrenally Directed Medical Therapies for Cushing Syndrome.
Tritos NA
J Clin Endocrinol Metab; 2021 Jan; 106(1):16-25. PubMed ID: 33118025
[TBL] [Abstract][Full Text] [Related]
2. Advances in medical therapies for Cushing's syndrome.
Tritos NA; Biller BM
Discov Med; 2012 Feb; 13(69):171-9. PubMed ID: 22369976
[TBL] [Abstract][Full Text] [Related]
3. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
Varlamov EV; Han AJ; Fleseriu M
Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
[TBL] [Abstract][Full Text] [Related]
4. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole.
Feelders RA; Hofland LJ; de Herder WW
Neuroendocrinology; 2010; 92 Suppl 1():111-5. PubMed ID: 20829630
[TBL] [Abstract][Full Text] [Related]
5. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.
Kamenický P; Droumaguet C; Salenave S; Blanchard A; Jublanc C; Gautier JF; Brailly-Tabard S; Leboulleux S; Schlumberger M; Baudin E; Chanson P; Young J
J Clin Endocrinol Metab; 2011 Sep; 96(9):2796-804. PubMed ID: 21752886
[TBL] [Abstract][Full Text] [Related]
6. Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.
Fleseriu M; Castinetti F
Pituitary; 2016 Dec; 19(6):643-653. PubMed ID: 27600150
[TBL] [Abstract][Full Text] [Related]
7. Medical Management of Cushing Disease.
Tritos NA; Biller BMK
Neurosurg Clin N Am; 2019 Oct; 30(4):499-508. PubMed ID: 31471057
[TBL] [Abstract][Full Text] [Related]
8. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.
Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
J Clin Endocrinol Metab; 2019 Aug; 104(8):3437-3449. PubMed ID: 31127821
[TBL] [Abstract][Full Text] [Related]
9. What is the role of medical therapy in adrenal-dependent Cushing's syndrome?
Braun LT; Reincke M
Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101376. PubMed ID: 32063487
[TBL] [Abstract][Full Text] [Related]
10. Medical therapy in severe hypercortisolism.
Marques JVO; Boguszewski CL
Best Pract Res Clin Endocrinol Metab; 2021 Mar; 35(2):101487. PubMed ID: 33518458
[TBL] [Abstract][Full Text] [Related]
11. Cushing's disease: adrenal steroidogenesis inhibitors.
Pivonello R; Simeoli C; Di Paola N; Colao A
Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
[TBL] [Abstract][Full Text] [Related]
12. Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome.
Daniel E; Newell-Price JD
Eur J Endocrinol; 2015 Jun; 172(6):R263-80. PubMed ID: 25637072
[TBL] [Abstract][Full Text] [Related]
13. New prospects for drug treatment in Cushing disease.
Barahona Constanzo MJ; del Pozo Picó C
Endocrinol Nutr; 2012 Dec; 59(10):599-605. PubMed ID: 23036936
[TBL] [Abstract][Full Text] [Related]
14. Approach to the Patient Treated with Steroidogenesis Inhibitors.
Castinetti F; Nieman LK; Reincke M; Newell-Price J
J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
[TBL] [Abstract][Full Text] [Related]
15. Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.
Detomas M; Altieri B; Deutschbein T; Fassnacht M; Dischinger U
Front Endocrinol (Lausanne); 2022; 13():903545. PubMed ID: 35769081
[TBL] [Abstract][Full Text] [Related]
16. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors.
Engelhardt D; Weber MM
J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):261-7. PubMed ID: 8043488
[TBL] [Abstract][Full Text] [Related]
17. Drugs in the medical treatment of Cushing's syndrome.
Schteingart DE
Expert Opin Emerg Drugs; 2009 Dec; 14(4):661-71. PubMed ID: 19939210
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological management of Cushing's syndrome: an update.
Dang CN; Trainer P
Arq Bras Endocrinol Metabol; 2007 Nov; 51(8):1339-48. PubMed ID: 18209872
[TBL] [Abstract][Full Text] [Related]
19. Advances in the Medical Treatment of Cushing Disease.
Tritos NA; Biller BMK
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):401-412. PubMed ID: 32741479
[TBL] [Abstract][Full Text] [Related]
20. Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients.
Bonnet-Serrano F; Poirier J; Vaczlavik A; Laguillier-Morizot C; Blanchet B; Baron S; Guignat L; Bessiene L; Bricaire L; Groussin L; Assié G; Guibourdenche J; Bertherat J
Eur J Endocrinol; 2022 Aug; 187(2):315-322. PubMed ID: 35699971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]